SOLENO THERAPEUTICS INC (SLNO) Stock Overview
USA - NASDAQ:SLNO - US8342033094 - Common Stock
SLNO Key Statistics, Chart & Performance
The current stock price of SLNO is 68.16 USD. In the past month the price increased by 0.72%. In the past year, price increased by 37.34%.
SLNO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.07 | 394.23B | ||
| AMGN | AMGEN INC | 12.56 | 147.49B | ||
| GILD | GILEAD SCIENCES INC | 14.55 | 139.74B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.34 | 101.35B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.29 | 59.43B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.66B | ||
| ARGX | ARGENX SE - ADR | 77.57 | 44.01B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.82 | 39.57B | ||
| INSM | INSMED INC | N/A | 29.94B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.58B | ||
| NTRA | NATERA INC | N/A | 22.38B | ||
| BIIB | BIOGEN INC | 8.65 | 20.31B |
Related stock screener links
About SLNO
Company Profile
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is headquartered in Redwood City, California and currently employs 133 full-time employees. The company went IPO on 2014-10-23. The firm is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The firm has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
Company Info
SOLENO THERAPEUTICS INC
100 Marine Parkway, Suite 400
Redwood City CALIFORNIA 94065 US
CEO: Anish Bhatnagar
Employees: 133
Phone: 16502138444
SOLENO THERAPEUTICS INC / SLNO FAQ
What is the stock price of SOLENO THERAPEUTICS INC today?
The current stock price of SLNO is 68.16 USD. The price increased by 4.93% in the last trading session.
What is the ticker symbol for SOLENO THERAPEUTICS INC stock?
The exchange symbol of SOLENO THERAPEUTICS INC is SLNO and it is listed on the Nasdaq exchange.
On which exchange is SLNO stock listed?
SLNO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SOLENO THERAPEUTICS INC stock?
16 analysts have analysed SLNO and the average price target is 120.97 USD. This implies a price increase of 77.48% is expected in the next year compared to the current price of 68.16. Check the SOLENO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SOLENO THERAPEUTICS INC worth?
SOLENO THERAPEUTICS INC (SLNO) has a market capitalization of 3.62B USD. This makes SLNO a Mid Cap stock.
How many employees does SOLENO THERAPEUTICS INC have?
SOLENO THERAPEUTICS INC (SLNO) currently has 133 employees.
What are the support and resistance levels for SOLENO THERAPEUTICS INC (SLNO) stock?
SOLENO THERAPEUTICS INC (SLNO) has a support level at 54.68 and a resistance level at 71.47. Check the full technical report for a detailed analysis of SLNO support and resistance levels.
Should I buy SOLENO THERAPEUTICS INC (SLNO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SLNO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SLNO, evaluating the profitability, health, valuation and growth aspects
- SOLENO THERAPEUTICS INC (SLNO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SOLENO THERAPEUTICS INC (SLNO) Sales and EPS estimates to see what analysts future expectations are.
- SOLENO THERAPEUTICS INC (SLNO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SOLENO THERAPEUTICS INC (SLNO) Insider and Institutional Ownership to learn about the owners and their transactions.
- SOLENO THERAPEUTICS INC (SLNO) Stock Chart to make your own analysis
- SOLENO THERAPEUTICS INC (SLNO) Latest news and press-releases to stay up to date.
Does SOLENO THERAPEUTICS INC (SLNO) stock pay dividends?
SLNO does not pay a dividend.
When does SOLENO THERAPEUTICS INC (SLNO) report earnings?
SOLENO THERAPEUTICS INC (SLNO) will report earnings on 2025-11-04, after the market close.
What is the Price/Earnings (PE) ratio of SOLENO THERAPEUTICS INC (SLNO)?
SOLENO THERAPEUTICS INC (SLNO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.14).
What is the Short Interest ratio of SOLENO THERAPEUTICS INC (SLNO) stock?
The outstanding short interest for SOLENO THERAPEUTICS INC (SLNO) is 14% of its float. Check the ownership tab for more information on the SLNO short interest.
SLNO Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to SLNO. When comparing the yearly performance of all stocks, SLNO turns out to be only a medium performer in the overall market: it outperformed 64.22% of all stocks.
SLNO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SLNO. SLNO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SLNO Financial Highlights
Over the last trailing twelve months SLNO reported a non-GAAP Earnings per Share(EPS) of -4.14. The EPS decreased by -69.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.49% | ||
| ROE | -75.41% | ||
| Debt/Equity | 0.21 |
SLNO Forecast & Estimates
16 analysts have analysed SLNO and the average price target is 120.97 USD. This implies a price increase of 77.48% is expected in the next year compared to the current price of 68.16.